GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Surgalign Holdings Inc (OTCPK:SRGAQ) » Definitions » Sloan Ratio %

Surgalign Holdings (Surgalign Holdings) Sloan Ratio % : -26.95% (As of Mar. 2023)


View and export this data going back to 2000. Start your Free Trial

What is Surgalign Holdings Sloan Ratio %?

Richard Sloan from the University of Michigan was first to document what is referred to as the "accrual anomaly". His 1996 paper found that shares of companies with small or negative accruals vastly outperform (+10%) those of companies with large ones.

Surgalign Holdings's Sloan Ratio for the quarter that ended in Mar. 2023 was -26.95%.

As of Mar. 2023, Surgalign Holdings has a Sloan Ratio of -26.95%, indicating there is a warning stage of accrual build up.


Surgalign Holdings Sloan Ratio % Historical Data

The historical data trend for Surgalign Holdings's Sloan Ratio % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Surgalign Holdings Sloan Ratio % Chart

Surgalign Holdings Annual Data
Trend Dec13 Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22
Sloan Ratio %
Get a 7-Day Free Trial Premium Member Only Premium Member Only 3.43 -24.98 -274.39 -6.48 6.78

Surgalign Holdings Quarterly Data
Jun18 Sep18 Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23
Sloan Ratio % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 8.77 -3.64 9.54 6.78 -26.95

Competitive Comparison of Surgalign Holdings's Sloan Ratio %

For the Medical Devices subindustry, Surgalign Holdings's Sloan Ratio %, along with its competitors' market caps and Sloan Ratio % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Surgalign Holdings's Sloan Ratio % Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Surgalign Holdings's Sloan Ratio % distribution charts can be found below:

* The bar in red indicates where Surgalign Holdings's Sloan Ratio % falls into.



Surgalign Holdings Sloan Ratio % Calculation

Earnings contain a lot of non cash earnings which is called accruals. The Sloan ratio is a way to identify firms with low non-cash or accrual-derived earnings relative to their cash flow.

Surgalign Holdings's Sloan Ratio for the fiscal year that ended in Dec. 2022 is calculated as

Sloan Ratio=(Net Income (A: Dec. 2022 )-Cash Flow from Operations (A: Dec. 2022 )
-Cash Flow from Investing (A: Dec. 2022 ))/Total Assets (A: Dec. 2022 )
=(-54.605--52.109
--7.256)/70.242
=6.78%

Surgalign Holdings's Sloan Ratio for the quarter that ended in Mar. 2023 is calculated as

Sloan Ratio=(Net Income (TTM)-Cash Flow from Operations (TTM))
-Cash Flow from Investing (TTM))/Total Assets (Q: Mar. 2023 )
=(-50.487--41.993
-9.754)/67.712
=-26.95%

Surgalign Holdings's Net Income for the trailing twelve months (TTM) ended in Mar. 2023 was -5.688 (Jun. 2022 ) + -9.833 (Sep. 2022 ) + -39.111 (Dec. 2022 ) + 4.145 (Mar. 2023 ) = $-50.49 Mil.
Surgalign Holdings's Cash Flow from Operations for the trailing twelve months (TTM) ended in Mar. 2023 was -13.271 (Jun. 2022 ) + -13.379 (Sep. 2022 ) + -6.321 (Dec. 2022 ) + -9.022 (Mar. 2023 ) = $-41.99 Mil.
Surgalign Holdings's Cash Flow from Investing for the trailing twelve months (TTM) ended in Mar. 2023 was -1.876 (Jun. 2022 ) + -2.322 (Sep. 2022 ) + -1.716 (Dec. 2022 ) + 15.668 (Mar. 2023 ) = $9.75 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Surgalign Holdings  (OTCPK:SRGAQ) Sloan Ratio % Explanation

A former University of Michigan researcher, Richard Sloan's 1996 paper found that shares of companies with small or negative accruals vastly outperform (+10%) those of companies with large ones. In fact, for the 40-year period between 1962 and 2001, buying the lowest accrual companies and shorting the highest accrual companies resulted in an average annual compounded return of 18%, more than double the S&P 500's 7.4% annual return over the same period.

According to How to Beat the Market with the Sloan Ratio:

If the Sloan Ratio is between -10% and 10%, the company is in the safe zone and there is no funny business with accruals.

If the Sloan Ratio is less than between -25% and -10% on the negative side, and between 10% and 25% on the positive side, this is a warning stage of accrual build up.

If the Sloan Ratio is less than -25% or greater than 25%, and this ratio is consistent over several quarters or even years, be careful. Earnings are highly likely to be made up of accruals.

As of Mar. 2023, Surgalign Holdings has a Sloan Ratio of -26.95%, indicating there is a warning stage of accrual build up.


Surgalign Holdings Sloan Ratio % Related Terms

Thank you for viewing the detailed overview of Surgalign Holdings's Sloan Ratio % provided by GuruFocus.com. Please click on the following links to see related term pages.


Surgalign Holdings (Surgalign Holdings) Business Description

Traded in Other Exchanges
N/A
Address
520 Lake Cook Road, Suite 315, Deerfield, IL, USA, 60015
Surgalign Holdings Inc is a global medical technology company advancing the science of spine care, focused on delivering innovative solutions that drive superior clinical and economic outcomes. The company continues to invest in clinically validated innovation to deliver the Best surgical outcomes and improve patient's lives. It markets products throughout the United States and in more than 50 countries worldwide through an expanding network of top independent distributors. The U.S. market accounts for the vast majority of revenue. It has commercial and design centers in San Diego, California, and Wurmlingen, Germany.
Executives
Elizabeth A. Lapuma director 520 LAKE COOK ROAD, SUITE 315, DEERFIELD IL 60015
Jill Kathleen Frizzley director P.O. BOX 1541, ONE BLUE HILL PLAZA, PEARL RIVER NY 10965
Paolo Amoruso officer: Chief Legal Officer C/O HYPERDYNAMICS CORPORATION, 12012 WICKCHESTER LANE, SUITE 475, HOUSTON TX 77079
David Lyle officer: Chief Financial Officer 6290 SEQUENCE DRIVE, SAN DIEGO CA 92121
Marc E. Mackey officer: EVP, Digital Surgery 520 LAKE COOK ROAD, SUITE 315, DEERFIELD IL 60015
Terry M. Rich officer: President, Global Spine 520 LAKE COOK ROAD, SUITE 315, DEERFIELD IL 60015
William Scott Durall officer: Chief Commercial Officer 520 LAKE COOK ROAD, SUITE 315, DEERFIELD IL 60015
Christopher Thunander officer: Chief Accounting Officer 520 LAKE COOK ROAD, SUITE 315, DEERFIELD IL 60015
Thomas Mceachin director 11621 RESEARCH CIRCLE, ALACHUA FL 32615
Nicholas J Valeriani director C/O EDWARDS LIFESCIENCES CORPORATION, ONE EDWARDS WAY, IRVINE CA 92614
Sheryl L Conley director C/O NEURONETICS, INC., 3222 PHOENIXVILLE PIKE, MALVERN PA 19355
Enrico Sangiorgio officer: EVP, International 520 LAKE COOK ROAD, SUITE 315, DEERFIELD IL 60015
Stuart F. Simpson director 520 LAKE COOK ROAD, SUITE 315, DEERFIELD IL 60015
Pawel Lewicki director 296 WOODWARD BLVD., TULSA OK 74114
Jeffrey C Lightcap director 152 W 57TH STREET 43RD FLOOR, NEW YORK NY 10019